Gene: FAM19A2

338811
TAFA-2|TAFA2
family with sequence similarity 19 member A2, C-C motif chemokine like
protein-coding
12q14.1
Ensembl:ENSG00000198673 MIM:617496 Vega:OTTHUMG00000170207 UniprotKB:Q8N3H0
NC_000012.12
PubMed
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.787e-1 (AD)  8.387e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNJ30.951
SYT130.949
FGF120.944
GABRB20.943
EPHA40.94
CNTNAP20.939
OLFM30.939
ATRNL10.939
CCDC85A0.939
C11orf870.938

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
REST-0.59
HEY2-0.59
CSAG1-0.564
CNN2-0.561
RAI14-0.56
WWTR1-0.555
CMTM3-0.55
CHST14-0.548
TGIF1-0.545
ACAP1-0.544

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0700461,2-dioleoyloxy-3-(trimethylammonium)propane"[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAM19A2 mRNA"22129739
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of FAM19A2 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of FAM19A2 mRNA19770486
C015001arsenitearsenite results in increased methylation of FAM19A2 promoter23974009
C487081belinostatbelinostat results in increased expression of FAM19A2 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of FAM19A2 gene25435355
C006780bisphenol Abisphenol A results in decreased expression of FAM19A2 mRNA22576693
C006780bisphenol Abisphenol A results in increased methylation of FAM19A2 gene22576693
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM19A2 mRNA28628672
C006780bisphenol Abisphenol A results in decreased methylation of FAM19A2 promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of FAM19A2 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM19A2 mRNA28628672
D002784Cholesterol"[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAM19A2 mRNA"22129739
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM19A2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM19A2 mRNA28628672
C118739entinostatentinostat results in increased expression of FAM19A2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM19A2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM19A2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FAM19A2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FAM19A2 mRNA28628672
C042720mercuric bromidemercuric bromide results in increased expression of FAM19A2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
D008727MethotrexateMethotrexate results in decreased expression of FAM19A2 mRNA24449571
D009532NickelNickel results in decreased expression of FAM19A2 mRNA25583101
D010634PhenobarbitalPhenobarbital results in increased expression of FAM19A2 mRNA19270015
D011374ProgesteroneProgesterone results in increased expression of FAM19A2 mRNA20864642
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of FAM19A2 mRNA25895662
C017947sodium arsenitesodium arsenite results in increased expression of FAM19A2 mRNA22714537
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FAM19A2 mRNA28922406
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FAM19A2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of FAM19A2 mRNA23179753|2627250
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of FAM19A2 gene25487561
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of FAM19A2 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25112515Admixture mapping identifies a quantitative trait locus associated with FEV1/FVC in the COPDGene Study. (2014 Nov)Parker MMGenet Epidemiol